Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-02-28
2011-10-04
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100, C424S196110
Reexamination Certificate
active
08029797
ABSTRACT:
An anti-HIV vaccine composition is disclosed. The vaccine comprises an combination of immunogenic peptide mixtures, which mixtures may be prepared in a single synthesis. The composition collectively represents the in vivo variability seen in immunogenic epitopes from highly variable regions of HIV. Immunization with the vaccine elicits broadly reactive immunity (CTL and T helper cell responses) against the divergent strains of HIV upon which it is based. The vaccine may be formulated to target regionally distinct variability based on an HIV clade predominant in a geographical region.
REFERENCES:
patent: 2002/0183484 (2002-12-01), Torres
patent: WO 01/24810 (2001-04-01), None
Walker, B. D., and D. R. Burton, 2008, Toward an AIDS vacine, Science 320:760-764.
Haigwood, N. L., 2004, Predictive value of primate models for AIDS, AIDS Reviews 6:187-198.
Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet, 266:1894-1898.
Desrosiers, R. C., 2004, Prospects for an AIDS vaccine, Nat. Med. 10(3):221-223.
Carlos, M. P., et al., 2000, Immunogenicity of a vaccine preparation representing the variable reigons of the HIV type 1 envelope glycoprotein, AIDS Res. Human Retrovir. 16(2):153-161.
Gahery-Segard, H., et al., 2000, Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine, J. Virol. 74(4):1694-1703.
HIV Sequence Compendium, 2003, Leitner, T., et al., eds., Published by Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM, LA-UR 04-7420 (http://www.hiv.lanl.gov./).
Azizi et al., “Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques”, Journal of Immunology, vol. 180, No. 4, Feb. 2008, pp. 2174-2186.
European Search Report dated Dec. 29, 2008, from European Patent Application No. 06705249.8.
Carlos et al., “Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein”,AIDS Res&Human Retroviruses16 (2), pp. 153-161 (2000).
Gahery-Segard et al.,“Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine”,J. Virol. 74 (4) pp. 1694-1703 (2000).
Marcus Altfeld et al., Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences, Journal of Virology, Jul. 2003, pp. 7330-7340, vol. 77, No. 13, American Society for Microbiology, Washington D.C., USA.
Anderson David Evander
Diaz-Mitoma Franscisco J.
Torres José Vidal
Choate Hall & Stewart LLP
Colantonio Jessica Russell
Lyon Charles E.
Parkin Jeffrey
Variation Biotechnologies Inc.
LandOfFree
Multivalent HIV immunogenic compositions comprising a pool... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent HIV immunogenic compositions comprising a pool..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent HIV immunogenic compositions comprising a pool... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272643